Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Parkinson’s disease therapeutics industry 3600 synopsis, 2016 - 2027 (USD Million)
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Route of administration trends
2.1.4 Patient trends
2.1.5 Regional trends
Chapter 3 Parkinson’s Disease Therapeutic Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 - 2027 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Growing aging population coupled with increasing prevalence of Parkinson’s disease
3.3.1.2 Increasing number of drug approvals
3.3.1.3 Growing awareness among the population
3.3.1.4 Growing funding in R&D
3.3.2 Industry pitfalls & challenges
3.3.2.1 High cost of the treatment
3.4 Growth potential analysis
3.4.1 By drug class
3.4.2 By route of administration
3.4.3 By patient
3.5 COVID-19 impact analysis
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 Competitive landscape, 2019
3.8.1 Competitive matrix analysis
3.9 PESTEL analysis
Chapter 4 Parkinson’s Disease Therapeutics Market, By Drug Class
4.1 Key segment trends
4.2 Levodopa/Carbidopa
4.2.1 Market size, by region, 2016 - 2027 (USD Million)
4.3 Dopamine Agonist
4.3.1 Market size, by region, 2016 - 2027 (USD Million)
4.4 Adenosine A2A Antagonist
4.4.1 Market size, by region, 2016 - 2027 (USD Million)
4.5 COMT Inhibitors
4.5.1 Market size, by region, 2016 - 2027 (USD Million)
4.6 MAO-B Inhibitors
4.6.1 Market size, by region, 2016 - 2027 (USD Million)
4.7 Glutamate Antagonist
4.7.1 Market size, by region, 2016 - 2027 (USD Million)
4.8 Others
4.8.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 5 Parkinson’s Disease Therapeutics Market, By Route of Administration
5.1 Key segment trends
5.2 Oral
5.2.1 Market size, by region, 2016 - 2027 (USD Million)
5.3 Subcutaneous
5.3.1 Market size, by region, 2016 - 2027 (USD Million)
5.4 Transdermal
5.4.1 Market size, by region, 2016 - 2027 (USD Million)
5.5 Others
5.5.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 Parkinson’s Disease Therapeutics Market, By Patient
6.1 Key segment trends
6.2 Adult
6.2.1 Market size, by region, 2016 - 2027 (USD Million)
6.3 Pediatric
6.3.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 7 Parkinson’s Disease Therapeutics Market, By Region
7.1 Key segment trends
7.2 North America
7.2.1 Market size, by country, 2016 - 2027 (USD Million)
7.2.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.4 Market size, by patient, 2016 - 2027 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.2.6 Canada
7.2.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3 Europe
7.3.1 Market size, by country, 2016 - 2027 (USD Million)
7.3.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.4 Market size, by patient, 2016 - 2027 (USD Million)
7.3.5 Germany
7.3.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.6 UK
7.3.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.7 France
7.3.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.8 Spain
7.3.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.8.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.9 Italy
7.3.9.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.9.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.9.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Market size, by country, 2016 - 2027 (USD Million)
7.4.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.4 Market size, by patient, 2016 - 2027 (USD Million)
7.4.5 Japan
7.4.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.6 China
7.4.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.7 India
7.4.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.8 Australia
7.4.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.8.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.9 South Korea
7.4.9.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.9.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.9.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5 Latin America
7.5.1 Market size, by country, 2016 - 2027 (USD Million)
7.5.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.4 Market size, by patient, 2016 - 2027 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5.7 Argentina
7.5.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.6 Middle East and Africa
7.6.1 Market size, by country, 2016 - 2027 (USD Million)
7.6.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.4 Market size, by patient, 2016 - 2027 (USD Million)
7.6.5 South Africa
7.6.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.6.3 Market size, by patient, 2016 - 2027 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2019
8.2 Kyowa Kirin Inc
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Product landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 Acadia Pharmaceuticals
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Product landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 Acorda Therapeutics Inc
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Product landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 Roche
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Product landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Sumitoma Dainippon pharma co ltd
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Product landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 Orion Corporation
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Product landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 H Lundbeck
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Product landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Amneal Pharmaceuticals
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Product landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 AbbVie Inc.
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Product landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 Boehringer Ingelheim
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Product landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 UCB
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Product landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Adamas Pharmaceutical Inc.
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Product landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
8.14 Teva Pharmaceutical Industries Ltd.
8.14.1 Business overview
8.14.2 Financial data
8.14.3 Product landscape
8.14.4 Strategic outlook
8.14.5 SWOT analysis
8.15 Desitin Arzneimittel GmbH
8.15.1 Business overview
8.15.2 Financial data
8.15.3 Product landscape
8.15.4 Strategic outlook
8.15.5 SWOT analysis
8.16 Supernus Pharmaceuticals
8.16.1 Business overview
8.16.2 Financial data
8.16.3 Product landscape
8.16.4 Strategic outlook
8.16.5 SWOT analysis
